Long-term safety of an eye injection for geographic atrophy from macular degeneration
Checks long-term safety of an eye injection, JNJ-81201887, in adults with geographic atrophy.
Plain-language title generated from the registry record
Registry title: A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Key facts
- Where
- Bristol, Headington, London, and Newcastle upon Tyne, United KingdomSee the 4 sites
- Phase
- Phase 2/3
Where in United Kingdom
- Bristol Eye HospitalBristol, United KingdomNo longer taking part
- Oxford Eye HospitalHeadington, United KingdomNo longer taking part
- The Retina Clinic LondonLondon, United KingdomNo longer taking part
- Royal Victoria InfirmaryNewcastle upon Tyne, United KingdomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Janssen Research & Development, LLC
- Trial code
- NCT06635148EU 2022-500747-21-00
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.Read full original descriptionShow less
Long-term Extension Study for Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
Inclusion: Participants who were enrolled and received treatment with JNJ-81201887 or sham in a parent clinical study (81201887MDG2001, 81201887MDG1003); Females (women of childbearing potential), male participants, and partners of male participants will not be required to use contraception in this LTE study; Must sign an informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study. The ICF may be signed by an impartial witness and/or legally designated representative depending on national/local regulations.
Exclusion: There are no exclusion criteria for this LTE study.